To selectively inhibit IRF4 in DLBCL as a therapeutic strategy, three human IRF4‐specific ASOs (hIRF4‐ASO#1, hIRF4‐ASO#2 and hIRF4‐ASO#3) were tested for their therapeutic activity in vitro and in vivo. Here, IRF4 is linked to diffuse large B-cell lymphoma.